Decoding Early Placental Dysfunction Through Maternal Biomarker Patterns: A Novel Approach to Predicting Pregnancy Complications
DOI:
https://doi.org/10.5281/zenodo.23194190Keywords:
Placental Dysfunction; Maternal Biomarkers; Pre-Eclampsia; PlGF; sFlt-1; PAPP-A; Fetal Growth Restriction; Pregnancy ComplicationsAbstract
Placental dysfunction is a major contributor to adverse pregnancy outcomes, including pre-eclampsia, fetal growth restriction, small-for-gestational-age birth, stillbirth, and medically indicated preterm delivery. These complications are frequently preceded by abnormal placental development, impaired trophoblast invasion, altered angiogenesis, and reduced uteroplacental perfusion. Because clinical manifestations often emerge after placental pathology has progressed, early prediction remains a key objective in obstetric research and clinical practice. This research paper examines the potential of maternal biomarker patterns for identifying early placental dysfunction and predicting pregnancy complications. A literature-based research approach was used to evaluate evidence concerning pregnancy-associated plasma protein-A, placental growth factor, soluble fms-like tyrosine kinase-1, the sFlt-1/PlGF ratio, mean arterial pressure, and uterine artery Doppler indices. The findings indicate that low placental growth factor and pregnancy-associated plasma protein-A, together with elevated soluble fms-like tyrosine kinase-1 and sFlt-1/PlGF ratios, are associated with increased risk of pre-eclampsia and fetal growth restriction. The evidence further suggests that predictive performance improves when maternal biomarkers are integrated with clinical risk factors, obstetric history, blood-pressure measurements, and ultrasound findings. This integrated approach may support earlier risk stratification, targeted surveillance, and personalized antenatal care. Further prospective multicenter studies are needed to validate standardized, cost-effective, and equitable biomarker-based prediction models.




